GLP-1 Innovation and Oversight Shaping the Future of Therapeutic Access

Originally approved for metabolic disorders such as diabetes and obesity, GLP-1 receptor agonists are now being studied for a range of expanded therapeutic applications, including musculoskeletal, reproductive, neurological and behavioral health disorders.

This panel brings together several industry experts to discuss the growing potential of GLP-1s in new areas of care, focusing on clinical development, regulatory strategies and market impact.

What you’ll learn:

• Emerging therapeutic areas where GLP-1s are showing promise
• Clinical, regulatory and reimbursement barriers to expanded use
• Strategies for advancing development and commercial uptake in new indication

Panelists (full titles):
Jayne Hornung, Chief Clinical Officer, MMIT
Joseph P. Schacht, Ph.D., Associate Professor, Department of Psychiatry, University of Colorado School of Medicine
Patrick F. Smith, PharmD, Senior Vice President, Translational Science, Certara
Nicole Snow, PharmD, BCSCP, CSP, Senior Clinical Pharmacy Liason, Olympia Pharmaceuticals